Table 2 Clinical and laboratory data of studied SLE patient
SLE patient (n = 23) | WBC/mm3 | PLT/(μL) | Anemia | Proteinuria | CRP (mg/mL) | ESR (mm/hour) | RF (IU/mL) | ANA | Anti-dsDNA | Anti-SSA-Ro | Lupus anticoagulant antibody | Anti-cardiolipin antibody | C3/C4 deficiency | Seizure | Arthritis | Serositis | Alopecia | Oral ulcer | Skin lesion | Photosensitivity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 5100 | 327,000 | – | – | 10.5 | 26 | 64 | + | – | + | – | – | – | – | + | – | + | – | + | + |
2 | 4400 | 430,000 | – | – | 11.8 | 27 | 11.4 | + | – | – | – | – | – | – | + | – | + | – | + | + |
3 | 2900 | 200,000 | – | + | 5.1 | 7 | 8.6 | + | + | – | – | – | – | – | + | + | + | + | – | + |
4 | 6300 | 205,000 | – | – | 4.3 | 14 | 19.4 | + | – | – | + | – | + | – | + | – | – | – | + | + |
5 | 6900 | 431,000 | – | – | 6.8 | 13 | 12.6 | + | + | – | – | – | – | – | + | – | – | – | + | + |
6 | 4200 | 431,000 | – | – | 10.5 | 10 | 29.5 | + | – | – | – | – | – | – | + | + | – | – | + | + |
7 | 6300 | 341,000 | – | – | 13.2 | 5 | 17.4 | + | + | – | – | – | – | – | + | – | + | – | + | + |
8 | 4400 | 384,000 | – | – | 5.5 | 9 | 9.09 | + | – | + | – | – | – | – | + | – | + | – | + | + |
9 | 3100 | 421,000 | – | – | 6.5 | 4 | 6.71 | + | + | – | + | – | – | – | + | + | + | – | + | + |
10 | 5700 | 293,000 | – | – | 7.1 | 4 | 5.3 | – | + | – | – | – | – | – | + | – | + | – | + | + |
11 | 9400 | 230,000 | – | – | 3.2 | 4 | 4.1 | + | + | – | – | – | – | – | + | – | – | – | + | + |
12 | 8400 | 432,000 | – | – | 6.4 | 26 | 16.2 | + | – | – | + | – | – | – | + | – | – | + | + | + |
13 | 9600 | 305,000 | – | – | 0.4 | 5 | 2.7 | + | + | – | – | – | – | – | + | – | – | – | + | + |
14 | 5700 | 393,000 | – | – | 15.2 | 58 | 14.3 | + | + | – | – | – | + | – | + | – | – | – | + | + |
15 | 7500 | 287,000 | – | – | 18.3 | 47 | 128.8 | + | – | – | – | – | – | – | + | – | – | – | + | + |
16 | 3300 | 375,000 | + | – | 9.7 | 6 | 5.1 | + | + | – | – | – | – | – | + | – | + | – | _ | + |
17 | 4800 | 447,000 | – | – | 4.5 | 8 | 9.2 | + | + | – | – | – | – | – | + | – | + | – | + | + |
18 | 7100 | 307,000 | – | – | 13.1 | 17 | 8.8 | + | – | – | – | – | – | – | + | – | + | – | – | – |
19 | 7000 | 387,000 | – | – | 14.1 | 32 | 129.6 | – | – | + | – | + | + | – | + | – | – | – | + | + |
20 | 8900 | 270,000 | – | – | 6.1 | 26 | 14.5 | + | + | – | – | – | – | + | + | – | + | + | + | + |
21 | 5200 | 422,000 | – | – | 8.4 | 18 | 22.1 | + | – | – | – | – | – | – | + | – | – | – | + | + |
22 | 6900 | 394,000 | – | – | 10.8 | 14 | 8.41 | + | – | – | – | – | – | – | + | + | + | – | + | + |
23 | 3500 | 110,000 | – | – | 3.7 | 24 | 6.7 | + | + | – | – | – | – | – | + | – | + | – | + | + |
All (mean ± SD) or percentage | 6335 ± 1811 | 340,087 ± 91,498 | 4.3% | 4.3% | 8.4± 4.4 | 17.5 ± 14.2 | 24.1 ± 35.4 | 91.3% | 52.17% | 13% | 13% | 4.3% | 13% | 4.3% | 100% | 17.3% | 56.5% | 13% | 86.9% | 95.6% |